# Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients

> **NCT03987308** · NA · RECRUITING · sponsor: **Beijing Hospital** · enrollment: 115 (estimated)

## Conditions studied

- Type 2 Diabetic Patients
- T2DM (Type 2 Diabetes Mellitus)
- T2DM

## Interventions

- **DRUG:** Beinaglutide
- **DRUG:** Insulin aspart

## Key facts

- **NCT ID:** NCT03987308
- **Lead sponsor:** Beijing Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-07-02
- **Primary completion:** 2025-09
- **Final completion:** 2025-12
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2025-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03987308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03987308, "Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03987308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*